News

APP has nine products manufactured at its Puerto Rico facility, including doxycycline, azithromycin and diphenhydramine. The company anticipates manufacturing more than 19 million units in Puerto Rico during

The announcement follows the FDA’s peripheral and central nervous system drugs advisory committee’s unanimous decision in December 2007 to recommend Xenazine for approval. Cambridge owns the worldwide rights

The shares of common stock were issued in a private placement transaction under Regulation D of the Securities Act of 1933 and have not been registered under the

Under the terms of the 2006 agreement between Seikagaku (SKK) and Can-Fite, Can-Fite will receive a consideration of $1 million upon clinical trial initiation. Under the agreement, Can-Fite

Curasan, based in Research Triangle Park, North Carolina, which had been marketing the family of bone regeneration and membrane products in the US since 2004, will now be

Under the letter of intent (LOI), Trimedyne has offered to license seven of its US patents and two US patent applications exclusively to FemSuite for any use in

Celsion and Yakult have executed a letter of intent relating to the commercialization of ThermoDox for the Japanese markets, which is subject to the execution of definitive agreements.

The company expects to launch the product at the end of the fourth quarter of 2008. Zhiqiang Han, president and COO of BMP Sunstone, said: “We are excited

After the acquisition, SIS will remain in Herzogenrath, near Aachen, Germany and will be renamed to ‘Bruker Nano’. Frank Saurenbach and Hans-Achim Fuss will continue to lead the